Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.

Commercial Deals

Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics

The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.

Companies Leadership

Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success

Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.

Clinical Trials Rare Diseases

Biopharma’s Must-Know Q4 Catalysts

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too. 

Clinical Trials Companies

Sun Backs India-First Stroke Drug From Pharmazz

Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial.  The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.

Commercial India

Alnylam/Roche’s Zilebesiran Affirms Efficacy, But Commercially Relevant Data Await

The KARDIA-1 monotherapy study was successful, but KARDIA-2 will give a better sense of the market opportunity.

Clinical Trials Cardiovascular

Corteria Rides Wave Of Renewed Interest In Heart Failure

A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.

Financing Cardiovascular

Johnson & Johnson Gets Its Aprocitentan Money Back

The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market. 

Deals Blood & Coagulation Disorders

Now Europe’s Most Valuable Company, Can Novo Nordisk Live Up To Investor Expectations?

Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?

Metabolic Disorders Cardiovascular

Bayer Expands Kerendia Program In Competitive Heart Failure Space

The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of

Clinical Trials Business Strategies

LIB Therapeutics Has An Unorthodox Funding Method And Big Plans

Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers. 

Clinical Trials Commercial

LIB Therapeutics Looks Competitive With Big Pharma in Hypercholesterolemia

Phase III results with lerodalcibep are in the same ballpark as heavy-hitting established PCSK9 inhibiting drugs.

Clinical Trials Companies
See All
UsernamePublicRestriction

Register